A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

Inclusion Criteria:

- Provision of informed consent prior to any study specific procedures

- Female or male aged ≥18 years

- History of type 2 diabetes mellitus for more than 12 months

- HbA1c≥7.0% and ≤11.0%

- Stable antidiabetic treatment during the last 12 weeks up to randomization

- eGFR 25-75 mL/minute/1.73m2, inclusive

- Micro or macroalbuminuria (UACR 30 - 3500 mg/g)

- Treatment with ACE inhibitor or an ARB for at least 3 months prior to screening

- Body mass index between 20 and 45 kg/m2

Exclusion Criteria:

- Any of the following CV/Vascular Diseases within 3 month prior to signing the consent
at Visit 1:

- Myocardial infarction

- cardiac surgery or revascularization (CABG/PTCA)

- unstable angina

- unstable HF

- New York Heart Association (NYHA) Class III-IV

- transient ischemic attack (TIA) or significant cerebrovascular disease

- unstable or previously undiagnosed arrhythmia

- Significant hepatic disease, including, but not limited to, chronic active hepatitis
and/or severe hepatic insufficiency

- Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) > 3X ULN

- Total Bilirubin (TB) >2 mg/dL (34.2 μmol/L)

- History of acute kidney injury requiring renal replacement therapy (dialysis or
ultrafiltration) or any biopsy or imaging verifying intercurrent kidney disease other
than diabetic nephropathy or diabetic nephropathy with nephrosclerosis

- Ongoing treatment with a SGLT2 inhibitor, GLP-1 agonist or DPP4 inhibitors

- Any condition which, in the judgment of the Investigator, may render the patient
unable to complete the study or which may pose a significant risk to the patient or
patient suspected or with confirmed poor protocol or medication compliance